Capital Fund Management S.A. Biocryst Pharmaceuticals Inc Transaction History
Capital Fund Management S.A.
- $37.9 Billion
- Q4 2024
A detailed history of Capital Fund Management S.A. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Capital Fund Management S.A. holds 59,327 shares of BCRX stock, worth $546,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,327
Previous 357,615
83.41%
Holding current value
$546,401
Previous $2.72 Million
83.58%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$202 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$184 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$109 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$83.7 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$75 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.71B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...